Literature DB >> 9217591

Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis.

R Costello1, P Deegan, M Fitzpatrick, W T McNicholas.   

Abstract

PURPOSE: Hypercapnia is regarded as a poor prognostic indicator in chronic obstructive pulmonary disease (COPD), but many patients hospitalized with hypercapnia associated with an acute exacerbation of COPD revert to normocapnia during recovery. We wished to determine if this reversible hypercapnia represents a distinct pattern of respiratory failure in COPD, or simply a stage in the progression to chronic hypercapnia. We therefore compared the long-term clinical progression and survival of COPD patients with reversible hypercapnic respiratory failure (defined as type 2.1) to those with normocapnic (PaCO2 < 50 mm Hg; type 1) and also to those patients with chronic hypercapnic (PaCO2 > 50 mm Hg) respiratory failure (defined as type 2.2). PATIENTS AND METHODS: We prospectively followed for 5 years a cohort of 85 patients who had been admitted as emergencies during a 1-year period to the respiratory unit of a University teaching hospital with an exacerbation of COPD complicated by respiratory failure (PaO2 < 60 mm Hg). The main long-term outcome measures were survival and blood gas changes.
RESULTS: Sixty-eight (80%) patients survived the initial admission, and 17 (27%) survived 5 years. PaCO2 rose substantially more during exacerbations in type 2.1 patients (mean 15.8 mm Hg), compared with type 2.2 (mean 6.8 mm Hg) and type 1 patients (mean 1.5 mm Hg). We analyzed 149 subsequent admissions among the survivors over the following 5 years. Type 2.1 patients had a better 5-year survival (28%) than type 2.2 (11% survival; P < 0.05), and similar to type 1 patients (33% 5-year survival). Only 24% of reversible hypercapnic patients developed chronic hypercapnia during long-term followup.
CONCLUSIONS: The data support reversible hypercapnia being a distinct manifestation of respiratory failure in COPD, with a similar prognosis to that of normocapnic respiratory failure.

Entities:  

Mesh:

Year:  1997        PMID: 9217591     DOI: 10.1016/S0002-9343(97)00017-X

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  36 in total

Review 1.  Home treatment of COPD exacerbations.

Authors:  D S Postma; N H Ten Hacken; H A Kerstjens; G H Koëter
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Management of an acute exacerbation of copd: are we ignoring the evidence?

Authors:  M K Johnson; R D Stevenson
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

3.  Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study.

Authors:  D Breen; T Churches; F Hawker; P J Torzillo
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

4.  Ventilatory and integrated physiological responses to chronic hypercapnia in goats.

Authors:  Nicholas J Burgraff; Suzanne E Neumueller; Kirstyn Buchholz; Thomas M Langer; Matthew R Hodges; Lawrence Pan; Hubert V Forster
Journal:  J Physiol       Date:  2018-10-14       Impact factor: 5.182

5.  Survival benefit of CPAP favors hypercapnic patients with the overlap syndrome.

Authors:  Philippe Jaoude; Thomas Kufel; Ali A El-Solh
Journal:  Lung       Date:  2014-01-23       Impact factor: 2.584

6.  Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial.

Authors:  Patrick B Murphy; Sunita Rehal; Gill Arbane; Stephen Bourke; Peter M A Calverley; Angela M Crook; Lee Dowson; Nicholas Duffy; G John Gibson; Philip D Hughes; John R Hurst; Keir E Lewis; Rahul Mukherjee; Annabel Nickol; Nicholas Oscroft; Maxime Patout; Justin Pepperell; Ian Smith; John R Stradling; Jadwiga A Wedzicha; Michael I Polkey; Mark W Elliott; Nicholas Hart
Journal:  JAMA       Date:  2017-06-06       Impact factor: 56.272

7.  Elevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophage.

Authors:  Naizhen Wang; Khalilah L Gates; Humberto Trejo; Silvio Favoreto; Robert P Schleimer; Jacob I Sznajder; Greg J Beitel; Peter H S Sporn
Journal:  FASEB J       Date:  2010-02-24       Impact factor: 5.191

Review 8.  The role of NIV in chronic hypercapnic COPD following an acute exacerbation: the importance of patient selection?

Authors:  Marieke L Duiverman; Wolfram Windisch; Jan H Storre; Peter J Wijkstra
Journal:  Ther Adv Respir Dis       Date:  2016-01-08       Impact factor: 4.031

Review 9.  Assessing respiratory drive and central motor pathway in humans: clinical implications.

Authors:  B Binazzi; B Lanini; G Scano
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 10.  Treatment of respiratory failure in COPD.

Authors:  Stephan Budweiser; Rudolf A Jörres; Michael Pfeifer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.